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1. ABSTRACT 41 
Patients with Inflammatory Bowel Disease increasingly use alternative and 42 
complementary therapies, for which appropriate evidence is often lacking. It is 43 
estimated that up to half of all patients with IBD use various forms of complementary 44 
and alternative medicine during some point in their disease course. Considering the 45 
frequent use of such therapies, it is crucial that physicians and patients are informed 46 
about their efficacy and safety in order to provide guidance and evidence-based 47 
advice. Additionally, increasing evidence suggests that some psychotherapies and 48 
mind-body interventions may be beneficial in the management of IBD, but their best 49 
use remains a matter of research. Herein, we provide a comprehensive review of some 50 
of the most commonly used complementary, alternative, and psychotherapy 51 
interventions in IBD. 52 
 53 




2. INTRODUCTION 56 
Inflammatory bowel disease (IBD) is a chronic disease where both medical and 57 
psychological factors have a major impact on patient´s quality of life (QoL). Many 58 
patients seek alternative and complementary therapies,1 for which appropriate 59 
evidence is often absent. However, considering the increasing use of such therapies, 60 
it is important that physicians are ready to provide evidence-based advice on their 61 
efficacy and potential risks.  62 
High levels of psychological and emotional distress, fatigue, anxiety, and depression 63 
are common among IBD patients, all complex symptoms that require integrative and 64 
appropriate management2,3. Psychotherapies and mind-body interventions may have 65 
beneficial impact on coping skills and stress management, but their best use remains 66 
undetermined.  67 
The aim of this topical review is to provide an overview on the most commonly used 68 
complementary, alternative, and psychotherapy interventions used in IBD. 69 
 70 
3. METHODS 71 
The European Crohn’s and Colitis Organisation (ECCO) organized a topical review 72 
consensus group on the issue of Complementary Medicine and Psychotherapy in IBD. 73 
ECCO topical reviews are developed from expert opinion consensus and are endorsed 74 
by ECCO. As controlled data are absent, a topical review is distinct from ECCO 75 
consensus guidelines and is intended to provide guidance in clinical areas where 76 
scientific evidence is lacking. An open call was announced to all ECCO members; 15 77 
individuals were selected based on their expertise in the topic. Three subgroups were 78 
formed. Working Group 1 focused on biologically-based practices with the goal of 79 
reviewing products such as herbal medicines, probiotics, marijuana, vitamins, and 80 
other dietary supplements. Working Group 2 focused on mind-body practices and 81 
psychotherapy interventions, with the goal of reviewing the main psychological 82 
domains that are altered in IBD (anxiety, depression, fatigue, etc). The available 83 
evidence for the use of hypnosis, yoga, and psychotherapy interventions was 84 
reviewed. Finally, Working Group 3 focused on manipulative and body-based 85 
practices such as acupuncture and exercise. 86 
All working groups performed a systematic literature search of their topic. Discussions 87 
of the published evidence among the working group members and a preliminary voting 88 
round took place. The working parties met in Vienna in February 2018 to agree on the 89 
statements. Statements were accepted when 80% or more of the participants were in 90 
agreement; statements were henceforth termed an agreed Current Practice 91 
Position. The group leaders and their respective working group wrote the final section 92 
for each subgroup. It is intended that the statements are read in context, with qualifying 93 
comments and not in isolation. The final text was edited for consistency of style by the 94 
steering committee and one member of the Guidelines Committee of ECCO who were 95 
not involved in the consensus. We recognize that not all products or interventions have 96 
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been included in this review as we chose to focus only on those that are most widely 97 
used.  98 
 99 
4. HERBAL THERAPIES AND DIETARY SUPPLEMENTS 100 
 101 
Many studies have assessed a wide range of herbal therapies and different herbal 102 
preparations in IBD. These are summarized in Table 1.  103 
 104 
a. Cannabis and other herbal therapies  105 
 106 
Current Practice Position 3.1 107 
Although the use of Cannabis may be associated with a reduction of some symptoms 108 
in IBD, there is no good evidence to show that it positively affects the course of disease 109 
 110 
A retrospective observational study on 30 patients showed promising results for 111 
Cannabis for the treatment of active Crohn’s disease (CD).4 A RCT assessed 22 112 
patients who received either Cannabis sativa or placebo cigarettes.5 Response rates 113 
and QoL, but not remission rate or reduction of C-reactive protein (CRP), were higher 114 
in the intervention group.5 Side effects did not differ between the groups.  115 
 116 
Two small controlled studies reported on the use of Artemisia absinthium (wormwood), 117 
a herbaceous plant, compared to placebo6 or standard treatment7 for the treatment of 118 
active CD (Table 1). 119 
 120 
Current Practice Position 3.2 121 
 122 
Curcumin as a complementary therapy to 5-aminosalicylic acid (5-ASA) may be 123 
effective in inducing remission in mild-to-moderately active ulcerative colitis (UC). 124 
Curcumin, psyllium, and an herbal preparation consisting of myrrh, chamomile, and 125 
coffee charcoal may be effective as complementary maintenance therapy in UC. 126 
 127 
For maintenance of remission in CD, a Boswellia extract compared to placebo was 128 
investigated in a RCT of 82 patients. There were no significant differences between 129 
the groups after 12 months. There were no serious adverse events in both groups.8 130 
Another study tested the effects of a traditional Japanese herbal preparation 131 
(daikenchuto) compared to 5-ASA and azathioprine among patients who underwent 132 
surgery. The results of this study indicated a significantly lower 3-year reoperation rate 133 
in the daikenchuto group.9 134 
 135 
High doses of Tripterygium wilfordii Hook F, a plant widely used in Chinese traditional 136 
medicine, led to prolonged remission and was well tolerated.10-13 For prevention of 137 
postoperative recurrence, Tripterygium wilfordii was less effective than azathioprine in 138 




For treatment of active UC, no differences regarding disease activity or remission rates 141 
were observed with curcumin enema plus oral mesalamine, as compared to placebo 142 
enema plus oral mesalamine.14 Oral curcumin plus oral mesalamine compared to 143 
placebo plus oral mesalamine resulted in more patients achieving endoscopic 144 
remission at the end of the 1-month treatment period and more patients with clinical 145 
improvement in the curcumin group.15 The incidence of adverse effects was not 146 
different between the treatments.  147 
 148 
A study on 44 patients compared Aloe vera gel to placebo and showed significant 149 
improvements in clinical signs and QoL after 4 weeks. Reductions in histologic score 150 
were also observed. No serious adverse events were reported.16  151 
 152 
Two studies evaluated the effects of HMPL-004 (Andrographis paniculata).17,18 No 153 
significant differences were found in one study, while in the other study higher 154 
response rates were observed with HMPL-004. The effects of pomegranate (Punica 155 
granatum) peels plus standard treatment were compared to placebo plus standard 156 
treatment in a study on 79 patients.19 Clinical treatment response was higher in the 157 
Punica granatum group, although this was not statistically significant. 158 
  159 
Wheat grass showed positive effects on disease activity, rectal bleeding, and 160 
abdominal pain.20 Another study on 126 patients assessed Sophora colon-soluble 161 
capsules or mesalamine over a period of 8 weeks21. There were no significant 162 
differences between groups regarding disease activity or laboratory measurements.  163 
 164 
For maintenance of remission in UC, curcumin had positive effects on disease activity 165 
and recurrence rate at 6 months.22 Curcumin is only available as an over-the-counter 166 
food supplement and relevant quality concerns regarding the preparation of the herbs 167 
may be an issue. 168 
  169 
Treatment with an herbal preparation of myrrh, chamomile, and coffee charcoal versus 170 
mesalazine exhibited no significant differences between the treatment groups 171 
regarding relapse rates, relapse-free time, endoscopy, and faecal biomarkers.23 The 172 
herbal preparation was well tolerated and had a good safety profile. This preparation 173 
is available as a drug at least in single countries in Europe.  174 
 175 
A study on 80 patients revealed that silymarin in addition to standard therapy had 176 
positive effects on haemoglobin levels, erythrocyte sedimentation rate, and disease 177 
activity.24 However, no significant differences between groups were reported.  178 
 179 
Preliminary evidence indicates that Holarrhena antidysenterica might be effective but 180 




Traditional Chinese Medicine (TCM) herbs are individualized based on symptoms and 183 
treatments are often based on classification of disease patterns. Accordingly, a 184 
conclusion about TCM herbs cannot be provided. However, TCM shows promising 185 
evidence.26-29 186 
 187 
Other herbs not yet evaluated by RCTs show promise in treating IBD. An open pilot 188 
study explored the effects of an anthocyanin-rich bilberry preparation in 13 patients 189 
with active UC. Over half (63.4%) of the patients achieved remission and 90.9% 190 
showed a response.30  191 
 192 
An open-label, dose-escalating study on 16 patients with active UC assessed tormentil 193 
in escalating doses for 3 weeks. During tormentil treatment, Colitis Activity Index 194 
decreased with highest effect sizes for 1800, 2400, and 3000 mg/day.31  195 
 196 
A non-randomized observational clinical study assessed an ayurvedic preparation 197 
(extract of Holarrhena antidysenterica, decoction of Ficus glomerata, powder 198 
combination of Cyperus rotundus, Mesua ferrea, and Symplocos racemose and Ficus 199 
glomerata decoction) in UC patients. Reductions in bowel movements, blood in the 200 
stool, and abdominal pain and improvements in general well-being and reduced intake 201 
of aminosalicylates were observed.32  202 
 203 
In summary, only few and small trials have investigated the role of herbs in the therapy 204 
of IBD patients with limited quality, which probably limits their routine use in the clinic.  205 
 206 
 207 
b. Vitamins and minerals 208 
 209 
Current Practice Position 3.3 210 
There is insufficient evidence to support the use of vitamins and minerals to induce or 211 
maintain remission in CD and UC 212 
 213 
Therapy with vitamin D,14,33-56 vitamin B,57-59 and vitamin K60 has been examined 214 
regarding their possible involvement in inflammatory pathways in IBD.  215 
 216 
Vitamin D deficiency is multifactorial in IBD and ranges between 10% to 75% across 217 
studies.61 The causes of vitamin D deficiency in patients with IBD include inadequate 218 
exposure to sunlight from reduced physical activity, inadequate dietary intake, 219 
impaired absorption, and impaired conversion of vitamin D.61The use of vitamin D as 220 
a therapy has been explored in vitamin D-deficient IL-10 knockout mice, which develop 221 
a rapidly progressive form of IBD. Disease was attenuated when these mice were 222 
given a high calcium and vitamin D diet.62 Some human studies have examined the 223 
role of vitamin D in IBD treatment.35,36,40,63 A study on use of vitamin D as maintenance 224 
therapy in CD patients in remission demonstrated that only 13% of the patients in the 225 
vitamin D replacement group relapsed during the 12-month study period compared to 226 
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29% in the placebo arm (p = 0.06).36 Another group compared the therapeutic effects 227 
of vitamin D replacement on bone health and CD activity and reported significant 228 
improvement during the 6-week follow-up period.35 An accelerated supplementation 229 
protocol for patients with CD or UC led to significant improvement in symptom-based 230 
activity scores (CDAI) but not in objective markers of inflammation.55 231 
 232 
A recent meta-analysis revealed that vitamin B12 levels were significantly lower in IBD 233 
patients than in healthy controls (standardized mean difference [SMD] -0.57 pg/mL; p 234 
< 0.001). However, there was significant heterogeneity in the included studies.59 235 
Mortimore and Florin reported the impact of high-dose vitamin B12 on the treatment 236 
of 10 consecutive IBD patients with dermatoses and showed improvement in 237 
cutaneous manifestations in 6 patients but not in those with only fistulising CD.58 238 
  239 
A recent review reported the prevalence of vitamin K deficiency in 111 paediatric IBD 240 
patients as 54% (CD) and 43.7% (UC), which correlated with higher disease activity 241 
and was most likely due to malabsorption and malnutrition.64 In a study from the 242 
Framingham Offspring population, vitamin K levels were inversely correlated with 243 
inflammatory markers (such as CRP); it was postulated that vitamin K may have anti-244 
inflammatory properties.65 One study reported no significant effects of vitamin K 245 
supplementation on bone health status in patients with CD.60 No study has 246 
investigated the effects of vitamin K supplementation on disease activity in IBD. 247 
 248 
c. Dietary supplements 249 
 250 
Current Practice Position 3.4 251 
There is insufficient evidence to support the use of diet supplements or specific diets 252 
to induce or maintain remission in CD and UC. However, future research should focus 253 
on diet as a complementary therapy  254 
 255 
This section is focused on dietary supplements other than enteral or parenteral 256 
nutrition. A more comprehensive review on diet and nutrition has been published in a 257 
separate Topical Review.66 258 
 259 
Common nutritional and dietary supplements comprise dietary fibre supplements 260 
(including prebiotics such as fructo-oligosaccharides) and fatty acids. The theorized 261 
mechanism underpinning the pathogenesis of IBD is an aberrant response by the 262 
mucosal immune system to microbiota in genetically susceptible individuals.67 Short-263 
chain fatty acids such as butyrate, arising from anaerobic fermentation of dietary fibre, 264 
are thought to positively influence the gut microbial composition and enhance colonic 265 
epithelial barrier function.68-80 The tested forms of fibre delivery in IBD range from 266 
dietary advice81 to fibre supplementation. Such supplementation includes 267 
psyllium67,81,82 and germinated barley.83-85 A systematic review of three RCTs in UC 268 
and one study in pouchitis revealed positive results for the use of fibre 269 
supplementation.67 No studies in CD showed added benefit 86-88, while others showed 270 
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equivalence 89,90. The trials examined showed conflicting results. Treatment of UC 271 
patients with germinated barley revealed a significant reduction in CRP but not in 272 
clinical activity indices.83 However, a separate study on UC patients revealed a 273 
significant reduction in clinical indices, but not CRP, after administration of germinated 274 
barley.85  275 
 276 
Fructo-oligosaccharides are prebiotics that are non-digestible, selectively fermentable, 277 
short-chain carbohydrates that stimulate the growth or activity of selected beneficial 278 
microbial species, such as Faecalibacterium prausnitzii and Bifidobacteria, resulting 279 
in potential health benefits to the host.88 An open-label pilot study on CD patients 280 
revealed a significant reduction in Harvey-Bradshaw index (HBI) and a non-significant 281 
reduction in inflammatory markers (CRP).91 This study was followed up with an 282 
adequately powered RCT that did not show a statistically significant different clinical 283 
response.88 Another RCT showed a significant reduction in HBI compared with 284 
baseline.92  285 
 286 
Specific diets, such as a diet high in salmon,93 have been examined for the treatment 287 
of IBD. The purported benefit of salmon is its high n-3 polyunsaturated fatty acid 288 
(PUFA) content (omega-3), with the additional benefit of peptides and phospholipids 289 
that accompany the fish (see also next paragraph).93 n-3 PUFAs are thought to 290 
produce an anti-inflammatory effect through the reduction of pro-inflammatory 291 
cytokines.93 A single-arm open-label pilot study on 12 patients that assessed the 292 
efficacy of a salmon-rich diet in patients with mild-to-moderate UC revealed that an 293 
intake of 600 g of salmon weekly over 12 weeks significantly reduced disease activity 294 
(p < 0.01), was associated with a trend towards lower CRP, and increased the anti-295 
inflammatory fatty acid index in biopsies and plasma.93 296 
 297 
Despite the current deficiency of quality data for diet supplements or specific diets in 298 
IBD, dietary therapies have the potential to be a meaningful complementary treatment 299 
and should be the focus of future research.     300 
 301 
d. Fish oil – omega-3 fatty acids 302 
 303 
Current Practice Position 3.5 304 
 305 
Omega-3 fatty acids might be beneficial in maintaining remission in CD. However, 306 
study quality and heterogeneity of trials limit these findings 307 
 308 
Fish oil, or n-3 PUFA, is thought to reduce production of IL-1, IL-6, and tumour necrosis 309 
factor.94 Oxidative stress, caused by an imbalance between the formation of reactive 310 
oxygen species and counteracting antioxidants occurs in several chronic inflammatory 311 
conditions, including IBD. Increasing the antioxidant level might reduce tissue damage 312 
and the inflammatory process. Fish and fish proteins may have such an antioxidant 313 
potential.95-97 A beneficial effect of fish oil and fish protein has been shown in some 314 
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animal models.95 Fish oil is found predominately in oily fish and in commercially 315 
produced fish oil capsules. Several studies have been conducted to test the effect of 316 
omega-3 fatty acid (FA) supplementation (also called n-3 or -3 FA) on biochemical 317 
and clinical outcomes in IBD.  318 
 319 
Among CD patients, two studies98,99 assessed the effect of n-3 FA compared with n-6 320 
FA on biochemical and clinical markers of inflammation as adjuvant therapy to 321 
corticosteroid treatment in patients with active disease. Nielsen et al (N = 31) showed 322 
that n-3 FA had immunomodulatory properties and might inhibit the increase of 323 
proinflammatory cytokines in contrast to n-6 FA. Eivindson et al (N  = 31) showed that 324 
disease activity and CRP decreased from baseline to week 9 in both the n-3 and the 325 
n-6 group.99 326 
   327 
A Cochrane review94 that assessed n-3 FA for the maintenance of remission in CD 328 
found a marginal benefit for n-3 FA over placebo in preventing relapse after one year 329 
(relapse rate, n-3 group 39% versus placebo 47%, 6 studies, 1039 patients, relative 330 
risk [RR] 0.77, 95% confidence interval [CI] 0.61–0.98). The same trend was also 331 
found in two other systematic reviews.100,101 Patients with CD had a significant 332 
reduction of relapse risk within one year compared with placebo in favour of n-3. 333 
However, there was heterogeneity in the pooled analyses, publication bias, and small 334 
negative trials were underestimated. In addition, no reduction in 1-year relapse rate 335 
was observed in the two high-quality studies EPIC1 and EPIC2.102 336 
  337 
In patients with UC, two systematic reviews found no difference in the relapse rate 338 
between n-3 FA supplementation and control groups.100,103 These studies did not 339 
record significant adverse events.  340 
 341 
A RCT on 211 patients assessed the effect of a combination of a nutritionally balanced 342 
oral supplement enriched with fish oil, fructo-oligosaccharides, gum arabic, vitamin E, 343 
vitamin C, and selenium on disease activity and medication use in adults with mild-to-344 
moderate UC. This study revealed similar rates of improvement of disease activity 345 
score and need for corticosteroids over a 6-month period as placebo104. Studies 346 
assessing the effect of fish oil on extraintestinal manifestations (such as joint pain) via 347 
administration of seal oil have shown promising results.105-107 A study that compared 348 
seal oil and cod liver oil found a tendency toward improvement in several joint pain 349 
parameters for both oils.107 Another study found positive results for duodenal 350 
administration of seal oil (rich in n-3 FAs) compared with soy oil (rich in n-6 FAs). Soy 351 
oil tended to aggravate joint pain.105   352 
 353 
e. Probiotics 354 
 355 
Current Practice Position 3.6 356 
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There is no evidence to support the use of prebiotics, probiotics, or both in patients 357 
with CD, neither in the induction nor maintenance of remission. There is no evidence 358 
to support the use of prebiotics, probiotics, or both in the postoperative CD patient. 359 
 360 
A recent overview summarized the evidence for probiotics in IBD patients.108 Two trials 361 
(N = 37) evaluated the efficacy of probiotics in the induction of remission in CD.109,110 362 
Both studies failed to show a clinical benefit. Studies evaluating maintenance of 363 
remission in quiescent CD patients (N = 195) also failed to show a statistically 364 
significant benefit.111,112 The role of probiotics in preventing relapse in CD patients in 365 
remission following surgically-induced remission (N = 333) remains controversial and 366 
no recommendations on their use can currently be given.113-116 In summary, there is 367 
little evidence for the use of probiotics in the treatment of CD.  368 
 369 
 370 
Current Practice Position 3.7 371 
Escherichia coli Nissle 1917 may be effective in inducing and is effective in maintaining 372 
remission in UC. A multistrain probiotic containing a combination of lactic acid bacteria, 373 
streptococcus,  and bifidobacteria may be effective in inducing and maintaining 374 
remission in UC. 375 
 376 
Eight studies evaluated the efficacy of probiotics in inducing remission in patients with 377 
active UC.117-124 One study compared nonpathogenic Escherichia coli Nissle 1917 b.d. 378 
for 12 weeks with mesalazine for 12 weeks (N = 116).121 There was no statistically 379 
significant difference between the two groups. The other seven studies (N = 535) were 380 
RCTs that compared probiotics with placebo.117-120,122-124 Three of these trials (N = 381 
319) used a multistrain probiotic containing eight different probiotics (Bifidobacterium 382 
breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus 383 
acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus 384 
bulgaricus, Streptococcus thermophilus).119,122,124 A recent systematic review108 385 
calculated on those three studies showed a number needed to treat of 5 for this 386 
multistrain probiotic (95% CI 4–10). Six RCTs evaluated the efficacy of probiotics 387 
(Bifidobacterium longum, Lactobacillus acidophilus, Bifidobacterium animalis subsp. 388 
lactis BB-12, Escherichia coli Nissle 1917, Streptococcus faecalis T-110, Clostridium 389 
butyricum TO-A, and Bacillus mesentericus) in the maintenance of remission in 390 
quiescent UC.125-130 Of these trials, three compared probiotics with 5-ASAs (N = 391 
555)126,127,130 and three compared probiotics with placebo (N = 122).125,128,129 In 392 
summary, probiotics showed efficacy in maintaining remission in UC patients. Since 393 
probiotics are usually well tolerated, they are useful alternatives to conventional 394 
medical therapy especially in UC patients. 395 
 396 
 397 




A significant proportion of IBD patients report or suffer from depression, anxiety, or 400 
both.  The prevalence rates of these disorders have been evaluated in four systematic 401 
reviews131-134 and two large observational studies,135,136 where they were compared 402 
between IBD and healthy and medically ill controls. 403 
 404 
a. Anxiety 405 
 406 
Current Practice Position 4.1 407 
 408 




Current Practice Position 4.2 413 
 414 
Anxiety is common in IBD, particularly during flares, with higher rates than in healthy 415 




Adults with IBD are more likely to develop anxiety before IBD onset; 70% of those with 420 
IBD and a lifetime history of anxiety or a mood disorder had a first episode of an anxiety 421 
disorder 10 years or more before the IBD diagnosis, whereas just 8% developed 422 
anxiety ≥2 years after IBD onset.136  423 
 424 
The pooled prevalence estimate for anxiety disorders in adult IBD patients is 20.5% 425 
(95% CI 4.9–36.5%).133 In CD, the pooled rate of anxiety-related symptoms is 19.1% 426 
(±3.63, 95% CI), 28.2% (±2.7, 95% CI) during remission, and 66.4% (±7.8, 95% CI) 427 
during flares (37% [±9.9, 95% CI]) 132. In UC the pooled rate of anxiety symptoms is 428 
31% (±14.2, 95% CI) as compared to 9.6% (±1.94, 95% CI) in healthy controls.132  429 
 430 
In studies where IBD cases were compared with medically ill controls, the pooled 431 
average rate of anxiety symptoms was 41.9% (±9.2, 95% CI) for IBD and 48.2% 432 
(±31.1, 95% CI) for medically ill controls.  433 
 434 
 435 
b. Depression 436 
 437 
 438 
Current Practice Position 4.3 439 
 440 






Current Practice Position 4.4 445 
 446 
Depression is common in IBD, particularly during flares, with higher rates than in 447 
healthy controls but not in patients with other chronic diseases  448 
 449 
Similar to anxiety, 54% of adult IBD patients with a lifetime history of anxiety or mood 450 
disorders had an onset of depression ≥2 years before IBD onset while 23% developed 451 
depression ≥2 years after IBD onset.136  452 
 453 
The pooled prevalence of depressive disorders in adults is 15.2% (95% CI 9.9–454 
20.5%). The pooled mean rate of depressive symptoms in IBD is 21.2% (±2.9, 95% 455 
CI) compared with 13.4% (±1.9, 95% CI) for healthy controls,132 with a higher 456 
prevalence in CD (25.3%, 95% CI 20.7–30%) than UC (16.7%, 95% CI 12.0–21.4%) 457 
and higher in active (40.7%, 95% CI 31.1–50.3%) versus inactive disease (16.5%, 458 
95% CI 7.4–25.5%).133 In the studies with medically ill controls, the pooled mean 459 
depression rate was 14.5% (±10.5, 95% CI) in IBD versus 28.4% (±17.7, 95% CI) in 460 
medically ill controls.  461 
 462 
c. Stress 463 
 464 
Patients often report stress as a major trigger of both disease and flares; this 465 
association has been examined in several studies.3,137-142 In a population-based study 466 
(N = 704), only high-perceived stress was associated with an increased risk of flare 467 
(adjusted odds ratio [OR] 2.40, 95% CI 1.35–4.26).140 In two prospective studies3,142 468 
each approximately with almost 500 participants, perceived stress was associated with 469 
symptomatic activity for both CD and UC. Patients with persistently active disease 470 
reported significantly higher stress than the persistently inactive group (mean stress 471 
at 3-month follow up 23.64, 95% CI 21.81–25.46 versus 17.46, 95% CI 16.46–472 
18.45).142 A smaller prospective study on CD patients (N = 101) also found stress, 473 
when paired with avoidance coping, as a significant predictor of flare.141  474 
 475 
 476 
Current Practice Position 4.5 477 
 478 
There is some evidence that stress is associated with a higher risk of relapse in IBD. 479 
There is no data on stress contributing to the aetiology of IBD 480 
d. Fatigue 481 
 482 




Even if inconsistently defined in the literature, fatigue is common in IBD patients and 485 
affects social functioning and QoL. Fatigue is associated with anxiety or depression, 486 
disease activity, sleep disturbances, reduced physical activity, medication use, and 487 
anaemia 488 
 489 
Despite extensively studied,2,143-160 fatigue has been inconsistently defined in the 490 
literature and commonly reported as a secondary outcome.144 Vogelaar et al found 491 
that several immune parameters were higher in fatigued patients, including TNF-α (p 492 
= 0.02) and IL-12 (p < 0.001); IL-6 was lower in these patients (p = 0.002).156 493 
 494 
The reported fatigue prevalence in IBD ranges between 22% to 48% in remission and 495 
44% to 86% in moderate-to-severe active disease.2,143,149 Almost 50% of newly 496 
diagnosed patients report fatigue.150 Severe anaemia can cause fatigue,146,147 but this 497 
is not the case with iron deficiency without anaemia.152 Other contributors include 498 
nutritional deficiency, smoking, and immune and genetic factors.145,146,148,156 In an 499 
observational study of 631 patients, 50% of patients with anaemia experienced daily 500 
fatigue, irrespective of disease activity.153 In a cross-sectional survey (N = 5382), 501 
prolonged use of corticosteroids was associated with fatigue versus non-use (55% 502 
versus 51%; p = 0.001) in patients aged >60 years.154 In a systematic review,148 503 
depression, stress, sleep disturbances, and anxiety (in this order) were associated 504 
with IBD fatigue. Fatigued patients reduce physical activity, with an estimated effect 505 
size of 1.02 (p = 0.04).155 Exercise programs could address the physical component 506 
of IBD fatigue.155,158 Fatigue reduced QoL in three studies (N = 84).147 Low QoL can 507 
in turn increase fatigue.151 508 
 509 
 510 
e. Irritable bowel syndrome (IBS) and functional symptoms in IBD  511 
 512 
The evidence on functional GI disorders is mostly limited to irritable bowel syndrome 513 
(IBS)-type symptoms.161-166 The pooled prevalence of IBS in IBD is approximately 39% 514 
(95% CI 30–48%),166 and is slightly lower during remission (35%, 95% CI 25–46%) 515 
than during flares  (44%, 95% CI 24–64%). When compared with controls, the OR for 516 
IBS was 4.89 (95% CI 3.43–6.98) in all IBD patients, 4.39 (95% CI 2.24–8.61) in 517 
remission, and 3.89 (95% CI 2.71–5.59) in active disease. The prevalence of IBS in 518 
CD was higher than in UC (46% versus 36%; OR 1.62, 95% CI 1.21–2.18). In a recent 519 
cross-sectional study (N = 6309), Abdalla et al161 observed a 20% rate of self-reported 520 
IBS diagnosis. Two large studies (N = 1321 with IBS-like symptoms, N = 6401 for all 521 
IBD patients) revealed worse QoL, higher levels of anxiety, depression, fatigue, sleep 522 
disturbances, pain interference, and decreased social satisfaction in patients with IBS-523 
like symptoms.161,165  524 
 525 
A cross-sectional study on children (N = 184)162 found that the prevalence of IBS-type 526 




Current Practice Position 4.7 529 
 530 
IBS is common in IBD and is associated with adverse patient-reported outcomes. IBS 531 
is slightly more common in CD than in UC 532 
 533 
 534 
f. Sleep  535 
 536 
Evidence regarding sleep disturbance in IBD is based on two case-control 537 
studies,167,168 five cohort studies,169-172 and one cross-sectional study.173 538 
 539 
The prevalence of sleep disorders in IBD ranges between 44% and 66% (versus 27–540 
55% in healthy controls and 67–73% in IBS).168,169,171,173 Even in remission, IBD 541 
patients (N = 119) report significantly more sleep disturbance (prolonged sleep 542 
latency, frequent sleep fragmentation, high use of sleeping pills, and poor overall sleep 543 
quality) than healthy controls; rates were however similar to IBS.167 Sleep disturbance 544 
is slightly more common in CD than in UC.167  Two prospective cohort studies171,172 (N 545 
= 3214) found an association between poor sleep quality and disease activity. Several 546 
cohort studies (N = 1468) suggest an association between poor sleep quality and an 547 
increased risk of IBD relapse at 6 months to 1 year.169,171,174 548 
 549 
 550 
Current Practice Position 4.8 551 
 552 
There is limited evidence on the frequency of sleep disturbance in IBD. Some studies 553 
report higher rates of sleep disturbance in IBD than in healthy controls 554 
 555 
In summary, anxiety and depression are common in IBD. High perceived stress is 556 
associated with a higher risk of relapse. Fatigue is common in IBD and is associated 557 
with higher disease activity and increased rates of anxiety and depression. IBS is 558 
common in IBD and is associated with poorer patient-reported outcomes. There is 559 
limited evidence on the frequency of sleep disturbance in IBD and further studies 560 
focused on sleep in IBD are needed.  561 
 562 
g. Cognitive Behavioural Therapy (CBT) 563 
 564 
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 566 
Cognitive behavioural therapy (CBT) has a short-term beneficial effect on QoL in 567 
adults with IBD. There is limited evidence on the efficacy of CBT in adolescents; early 568 




CBT is a type of psychotherapy that teaches patients to identify and modify unhelpful 571 
negative thinking styles and maladaptive behaviours. It has a shorter duration than 572 
traditional psychotherapies (6–12 weeks).139 Common elements of CBT include 573 
exploration of the links between cognitions and emotions, cognitive restructuring and 574 
challenging unhelpful thoughts, psycho-education, coping, and relaxation. 575 
 576 
The evidence on the effectiveness of CBT in IBD has been summarized in two meta-577 
analyses138,175 and two systematic reviews.139,176 CBT seems to improve the short-578 
term QoL in adults (N = 254, SMD 0.37, 95% CI 0.02–0.72),175 albeit with little or no 579 
effect on disease activity, anxiety, depression, and perceived stress.139,176 A positive 580 
short-term effect of CBT on QoL (SMD 0.70, 95% CI 0.21–1.18) and coping (SMD  581 
0.75, 95% CI 0.26–1.25) was noted in adolescents (N = 71).138 582 
 583 
 584 
h. Hypnotherapy 585 
 586 
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 588 
There is limited evidence on the efficacy of hypnotherapy to reduce IBD symptoms, 589 
maintain clinical remission, and increase QoL in UC 590 
 591 
The effectiveness of hypnotherapy (treatment involving deep relaxation, focused 592 
attention, and an enhanced ability to follow suggestions) has been studied in 593 
IBD.138,139,175,177 A small study showed an immune-modulating effect of a 50-minute 594 
session of gut-directed hypnotherapy in 17 patients with active UC.139,177 Three pre-595 
post hypnotherapy studies (N = 2, CD, with a 6-month follow up; N = 8, IBD; N = 15, 596 
severe UC with 5.4-year follow up) and one trial in UC (N = 23) have shown that 597 
hypnotherapy improves QoL and reduces bowel symptoms.139,177 One RCT in 598 
quiescent UC (N = 54) showed that gut-directed hypnotherapy maintains clinical 599 
remission (68% for hypnosis versus 40% of controls maintained remission for 1 year; 600 
p = 0.04).139,175,177  601 
 602 
 603 
i. Other psychotherapies 604 
 605 
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 607 
Psychodynamic therapy may reduce depressive and anxiety symptoms. Stress 608 
management has only modest benefits in reducing IBD symptoms and improving 609 
mental health or QoL. Solution-focused therapy (SFT) might be beneficial for patients 610 




The evidence on the effectiveness of psychodynamic therapy and as well as SFT in 613 
IBD is based on two meta-analyses and two systematic reviews138,139,175,176. Other 614 
psychotherapies such as psychodynamic (PD) therapy and stress management (SM) 615 
interventions have also been investigated in IBD.138,139,175,176 PD is derived from 616 
traditional psychoanalysis and focused on working with transference (i.e., the 617 
redirection of childhood emotions to a therapist). Common elements of PD are 618 
interpretation, empathic validation, free association, and analysis of transference, 619 
regression, and resistance.139 PD must be used as a long-term therapy (20–52 weeks 620 
in IBD trials). SM is focused on developing strategies to manage stress and includes 621 
breathing exercises, relaxation, biofeedback, and problem solving (typically 6–8 622 
sessions). SFT uses the patient’s past experiences to address current difficulties and 623 
relies on identifying solutions that worked in the past and finding exceptions to the 624 
patient’s problems (typically 5–6 sessions). No or minimal effect of PD, SM, and SFT 625 
on long-term disease activity have thus far been observed.138,139,175,176 Significant 626 
short-term improvements in QoL and fatigue were observed in patients with elevated 627 
fatigue scores receiving SFT.175 There is limited evidence for SM and PD to improve 628 
mental health and QoL.139,176 629 
 630 
j. Meditation, mindfulness, and relaxation 631 
 632 
Current Practice Position 4.12 633 
 634 
Meditation and relaxation may improve QoL and possibly decrease inflammatory 635 
activity in IBD. There is limited evidence on the effectiveness of mindfulness-based 636 
interventions on disease activity 637 
 638 
Meditation is a broad term encompassing practices aimed at reaching a heightened 639 
level of consciousness and concentration. Mindfulness is a type of meditation 640 
dedicated to being present in the moment. It involves activities where one focuses on 641 
a particular sensation, such as taste or smell, and brings the mind to breathing. 642 
Relaxation is a process of reducing tension in the body and mind and may involve 643 
breathing activities or tensing and relaxing different muscle groups. Meditation, 644 
mindfulness, and relaxation are often used as part of psychotherapies but also as 645 
standalone treatments to promote wellbeing. 646 
 647 
While older trials in IBD (N = 136) reported improvements in symptoms, psychosocial 648 
wellbeing, and QoL using relaxation and stress management, recent trials found 649 
benefit on QoL only (2 RCTs, N = 121).178 Two recent studies (N = 29179 and N = 60180) 650 
showed that mindfulness improved psychological and physical symptoms in IBD and 651 
reduced CRP levels.179 Norton et al181 showed pain reduction using relaxation, 652 
meditation, or both in four out of six studies. Timmer et al138 showed no evidence for 653 
the efficacy of relaxation in unselected adults with IBD.  654 
 655 
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 659 
There is limited evidence on the efficacy of yoga to reduce IBD symptoms. Yoga 660 
improves QoL in adults with IBD 661 
 662 
The largest survey performed to date (N = 235)182 reported that 16.3% of paediatric 663 
IBD patients (aged 2–22 years) practiced yoga, meditation, or tai chi, while the second 664 
survey (N = 67, aged 12–19 years) reported that 10% of patients practiced yoga.183 665 
One trial184 (N = 60, UC; N = 40, CD; all adults in remission) compared an 8-week 666 
yoga intervention to treatment as usual (TAU). The study showed yoga to be no 667 
different than TAU, except for colic pain that was reduced in the yoga group (p < 0.05). 668 
Another RCT185 (N = 77; adults with UC in remission) on patients with impaired QoL 669 
who received 12 sessions of yoga or written self-care advice showed yoga to be 670 
effective in improving QoL after 12 and 24 weeks (p = 0.018 and p = 0.022, 671 
respectively). Yoga also improved disease activity after 24 weeks (p = 0.029).  672 
 673 
In summary, CBT improves QoL in IBD over the short term. Although the evidence on 674 
the efficacy of hypnotherapy to reduce IBD symptoms is limited, the efficacy of 675 
hypnotherapy in functional gut disorders186 warrant future studies in IBD. PD therapy 676 
and SM may reduce depressive and anxiety symptoms, but not IBD severity. SFT 677 
might be beneficial for patients with fatigue. Meditation and relaxation may improve 678 
QoL and inflammatory activity in IBD. Evidence on the effect of mindfulness-based 679 
interventions on disease activity is limited and the role of this intervention in IBD 680 
management should be further explored. There is limited evidence on the efficacy of 681 
yoga to reduce IBD symptoms, but yoga may improve QoL in adults with IBD. 682 
 683 
6. MANIPULATIVE AND BODY-BASED INTERVENTIONS 684 
 685 
a. Moxibustion and acupuncture 686 
 687 
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 689 
There is insufficient evidence to support the use of moxibustion and acupuncture 690 
(either in monotherapy or in combination) for the treatment of active UC or CD  691 
 692 
The term acupuncture (AP) refers to the insertion of needles for remedial purposes 693 
into specific points (acupoint receptors).187 Moxibustion is a procedure involving the 694 
use of heat generated by burning material, which is then applied to certain areas of 695 
the body (usually AP points187) where it stimulates superficial and deep tissues of the 696 
skin.188 Several burning materials can be used, the most usual being moxa (herbal 697 
preparation containing Artemisia vulgaris). Direct moxibustion is applied directly to the 698 
skin around an acupuncture point, whereas indirect moxibustion or herb-partitioned 699 
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moxibustion (HPM) is performed with some insulating materials between the moxa 700 
cone and the skin.187-189  AP and moxa are often used in combination. 187  Several 701 
human studies have assessed the clinical benefit of these interventions in IBD 702 
(Supplementary Table 1).  703 
Moxibustion alone 704 
A systematic review and meta-analysis assessed the evidence of moxibustion alone 705 
for the treatment of UC;189 five RCTs conducted in China were included, three of which 706 
compared moxibustion with sulfasalazine (SASP) and the remaining two compared 707 
moxibustion to SASP and other drugs (antibiotics, steroids). The efficacy of 708 
moxibustion was based on physician’s assessment (recovery, marked improvement, 709 
improvement, and no change) or endoscopy. The meta-analysis suggested a small 710 
favourable effect of moxibustion when compared with SASP alone (RR 1.23, 95% CI 711 
1.04–1.46; p = 0.01) or SASP combined with steroids or antibiotics (RR 1.33, 95% CI 712 
1.11–1.59; p = 0.002) with overall low heterogeneity. However, all trials were non-713 
blinded and reported incomplete outcome measures, and were therefore considered 714 
to have a high risk of bias.189 Furthermore, non-standard measures of clinical and 715 
endoscopic activity were used, thus greatly limiting the conclusions.  716 
Acupuncture versus moxibustion 717 
Moxibustion and e-AP were compared as separate treatments in a randomized study 718 
of CD patients in sustained remission. Thirty-six patients were randomly assigned to 719 
e-AP or moxa treatment over 12 weeks. In both arms there was a significant reduction 720 
of CDAI and a significant increase in the Inflammatory Bowel Disease Questionnaire 721 
(IBDQ); no significant difference was seen between both interventions.190 722 
  723 
Acupuncture combined with moxibustion 724 
The efficacy and safety of AP with moxibustion were evaluated in patients with mild-725 
to-moderate CD; 92 subjects were randomly assigned to receive either active 726 
treatment (HPM with AP) or placebo (wheat-bran-partitioned moxa combined with 727 
superficial needle application in non-acupoints) over 12 weeks. Both groups had a 728 
significant reduction in the CDAI and IBDQ at week 12, which was significantly greater 729 
in the active treatment arm (p < 0.001). Patients in the active treatment group also 730 
showed a significant improvement in haemoglobin (p = 0.026), CRP levels (p = 0.008), 731 
and histopathological scores (p = 0.029) when compared with placebo. No significant 732 
difference was found in endoscopy.191  733 
Another randomized, single-blind trial evaluated the efficacy of the combined 734 
methods in reducing CDAI after 4 weeks of treatment. Patients with mild-to-moderate 735 
CD were randomly assigned to receive 10 AP sessions over 4 weeks or sham AP. 736 
All patients in the AP arm were treated with Artemisia Moxa. Fifty-one patients were 737 
treated (27 in the active arm and 24 in the control arm). While CDAI reduction was 738 
significantly higher in the treatment arm (p = 0.003), the overall remission rates were 739 
not statistically different between the two arms. QoL was improved in both arms 740 




Two large studies assessed the efficacy of AP combined with moxibustion in 743 
UC.193,194 In one study, 121 patients were randomly assigned to receive either AP (N 744 
= 76) or SASP 1 to 2 g four times/day (N = 45) over a period of 20 to 60 days. In the 745 
intervention group, 59% of patients entered remission as compared with 39% of 746 
patients in the control group. Low-quality trial design affected the validity of these 747 
results.193 In another study on 123 patients with mild-to-moderate UC, HPM with AP 748 
was compared with sham intervention (bran-partition moxibustion).194 A significant 749 
improvement (defined as disappearance of clinical symptoms and normal colonic 750 
mucosa by sigmoidoscopy) was observed in 52.5% of patients treated with HPM 751 
versus 24.5% of patients that received sham intervention. No baseline description of 752 
patient features  was provided (such as extent of colitis, Mayo score, concomitant 753 
therapies during the trial), making the results difficult to interpret.194 In another small 754 
RCT in mild-to-moderate UC, 29 patients were randomly assigned to receive AP plus 755 
moxibustion or sham AP for 5 weeks. Disease activity was measured by the Colitis 756 
Activity Index (CAI) and QoL with IBDQ and a 10-point VAS. The treatment group 757 
showed a significant decrease in CAI after treatment (p < 0.001) and the benefit was 758 
maintained throughout the 16-week follow-up (p < 0.001). Although patients in the 759 
control group showed an improvement in disease activity, treatment was significantly 760 
superior (p = 0.048). In the treatment group, CAI was statistically lower than that at 761 
baseline (p < 0.001). QoL was improved in both groups.195 762 
 763 
Finally, a meta-analysis examined the clinical efficacy of AP and/or moxibustion 764 
compared with SASP for the treatment of UC.196 The overall efficacy of AP alone, 765 
moxibustion alone, or AP combined with moxibustion was greater than the efficacy of 766 
SASP (RR 5.42, 95% CI 3.38–8.68; p < 0.0001). However, the trials were 767 
underpowered and were mostly of low quality with subjective assessments of 768 
efficacy.196 Additionally, true blinding was questioned to be even possible, as the 769 
acupuncturist always knows if the needle is inserted in an acupoint or not. Moreover, 770 
needle insertion can lead to nonspecific physiological responses and this could 771 
explain why in some studies an improvement was also obtained with sham 772 
acupuncture.197 773 
 774 
In summary, the low quality of the published studies, even if with positive results, 775 
precludes any valid conclusion and recommendations. 776 
 777 
b. Chiropractic treatment and Osteopathy 778 
 779 
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 781 
There is minimal evidence on the efficacy of chiropractic and osteopathy in the 782 
management of active CD  783 
 784 
Chiropractic and osteopathy are two different types of CAM. Chiropractic 785 
treatment involves manual therapy, usually spinal manipulation therapy, but also 786 
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manipulations of other joints and soft tissues. Osteopathy involves massage, 787 
stretching, pressure, and mobilization of various tissues or organs.198,199 A summary 788 
of the major studies on chiropractic and osteopathy can be found in Supplementary 789 
Table 2. 790 
 791 
In a longitudinal, population-based study of health outcomes in an IBD cohort, among 792 
patients that used CAM, 14% used chiropractic treatament.200,201 In a study from 793 
Sweden, 5.4% of IBD patients made use of chiropractic therapy compared with 5.7% 794 
of the normal population.202 795 
 796 
There is limited data on the use and benefit of chiropractic and osteopathy as CAM in 797 
IBD, with only two randomized trials published. In a single-blind study, CD patients in 798 
remission were randomised into two groups. The aim of the study was to determine if 799 
there was an improvement in IBDQ score following visceral osteopathic treatment. 800 
Fourteen patients received visceral osteopathic technique at the root of the mesentery. 801 
The root of the mesentery gives rise to the mesentery of the small intestine and is the 802 
region connected to the structures in front of the vertebral column. The control group 803 
(N=13) did not receive any osteopathic treatment and had virtual manipulation, which 804 
consisted of palpation of the small intestine and colon without action on the 805 
vasculature and innervations. Change in QoL was assessed using the IBDQ. The 806 
IBDQ score increased significantly (p < 0.001) in the group treated with osteopathy; 807 
no significant change was observed in the control group (p = 0.22).199 In another study, 808 
38 CD patients who were in remission receiving infliximab were randomly assigned 809 
2:1 to receive osteopathic or sham therapy at 15, 30, and 45 days after infliximab 810 
infusion. The severity of IBS-like symptoms was significantly reduced in patients 811 
receiving osteopathy (p = 0.01, p = 0.04, and p = 0.05 at day 30, 45, and 60, 812 
respectively).203 813 
 814 
There are currently no published studies evaluating chiropractic and osteopathy in 815 
patients with UC or IBDU. 816 
 817 
c. Exercise 818 
 819 
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 821 
Exercise can have beneficial effects on overall health, physical well-being, perceived 822 
stress, and QoL of IBD patients. There is promising but limited evidence on the role of 823 
exercise both in protection from IBD development and in disease management  824 
 825 
Regular exercise exerts anti-inflammatory effects, which may be mediated through a 826 
reduction in visceral fat mass (with a consequent decreased release of adipokines) 827 
and the induction of an anti-inflammatory environment.204,205 828 
  829 
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In a retrospective database analysis, a sedentary occupation was associated with a 830 
two-fold increase in IBD incidence.206 In two large prospective female 831 
cohorts, physical activity was inversely associated with risk of CD but not of UC.207 832 
Compared with women with low physical activity, the multivariate adjusted hazard ratio 833 
(HR) of CD among women with very high physical activity was 0.64 (95% CI 0.44–834 
0.94).207  Active women with at least a 27 metabolic equivalent task (MET) hours/week 835 
of physical activity had a 44% reduction (HR 0.56, 95% CI 0.37–0.84) in risk of 836 
developing CD compared with sedentary women with <3 MET hours/week.207 In a 837 
case-control study the RR of CD was inversely related to regular physical activity 838 
(weekly exercise, RR 0.6, 95% CI 0.4–0.9; daily exercise, RR 0.5, 95% CI 0.3–0.9).208 839 
Furthermore, in a recent meta-analysis it was demonstrated that physical activity has 840 
a protective effect against developing CD.209 No significant inverse association 841 
between physical activity and UC was observed.   842 
 843 
Exercise could be used in the treatment of IBD either for its anti-inflammatory potential 844 
or for symptom relief.210 Several studies have been performed on IBD patients (Table 845 
2)179,207,208,211-216 and have shown that exercise could be beneficial via a positive effect 846 
on QoL. However, these studies were limited by small sample size. In the largest study 847 
to date, 117 CD patients in remission where randomized to either a low-impact 848 
exercise program or no prescribed exercise. The primary endpoint was bone mineral 849 
density (g/cm2) measured at baseline and at 12 months at the hip and spine (L2–L4) 850 
by dual-energy x-ray absorptiometry. This study revealed that exercise was associated 851 
with increasing bone mineral density. Effects on disease activity were not 852 
measured.211 A prospective study216 on CD patients in remission (CDAI < 150) 853 
revealed that those with higher exercise levels were significantly less likely to develop 854 
active disease at 6 months. In UC patients in remission, those with higher exercise 855 
levels were also less likely, albeit non-significantly, to develop active disease at 6 856 
months. 857 
  858 
Data are lacking regarding the intensity and type of exercise. Furthermore, for active 859 
disease there is a possibility that exercise could exacerbate symptoms, as more 860 
rigorous exercise may cause gastrointestinal symptoms such as bloating, cramps, and 861 
urgency to defecate.217 A trial assessing two exercise regimens in adults with inactive 862 
or mildly active CD is currently underway.218 New technology, including next-863 
generation wearable physical activity trackers, could potentially improve exercise 864 
studies and might be used to promote physical activity219 in IBD patients. 865 
 866 
 867 
7. CONCLUSION 868 
Various types of CAMs and psychotherapy interventions are available. However, for 869 
most of them, the lack of rigorously conducted trials has hampered their use. 870 
Regarding psychotherapy and mind-body interventions, a positive effect on quality of 871 
life has been reported; effect in disease activity is less clear. Physicians should be 872 
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informed about the evidence behind most frequently used CAMs and be ready to 873 
provide advice to their patients. Further research is needed before strong 874 
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